The inhibitory effect of M2 macrophage-derived exosomes on gefitinib resistant lung adenocarcinoma cells through the MIF/TIMP1/CD74 axis by Jingcui Peng, Yan Zhang, Bin Li, Xin He, Cuimin Ding, Wenxia Hu

Get full text

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis by Xinyue Wang, Zhaona Li, Liuchun Wang, Yan Liang, Chun Huang, Peng Chen, Dingzhi Huang, Xia Song, Cuimin Ding, Changli Wang, Richeng Jiang

Get full text

Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial by Tianqing Chu, Hua Zhong, Zhuang Yu, Jing Wang, Yanqiu Zhao, Xiaoqian Mu, Xinmin Yu, Xun Shi, Qingming Shi, Maojing Guan, Cuimin Ding, Nan Geng, Jialin Qian, Baohui Han

Get full text

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A... by Yuequan Shi, Xiaoyan Liu, Anwen Liu, Jian Fang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Cuiying Zhang, Chengzhi Zhou, Yan Wang, Yongjie Shui, Siyuan Yu, Dongming Zhang, Jia Liu, Haoran Zhang, Qing Zhou, Xiaoxing Gao, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang, Xiangxiang Pan

Get full text

Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lun... by Yuankai Shi, Minghong Bi, Qingshan Li, Guolei Wang, Jianhua Chen, Mingjun Li, Jianhua Shi, Jiazhuan Mei, Yinghua Ji, Qingdi Xia, Yuanqing Feng, Shufeng Xu, Tongmei Zhang, Xiaohui Gao, Shubin Tang, Jie Weng, Zhuo Cao, Hongbo Wu, Xiubao Ren, Hua Xie, Hua Liu, Qiang Liu, Xing Yin, Xiaoyong Luo, Jun Chen, Haiming Zhang, Zhiyuan Guo, Cuimin Ding, Xin Jin, Rongli Sun, Sheng Yang

Get full text

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study by Jian Zhang, Ping Lu, Hui Zhao, Jianhua Chen, Wei Shi, Xiubao Ren, Yi Hu, Liping Wang, Hongmei Zhang, Chengchu Zhu, Jianping Xiong, Jianying Zhou, Jun Zhao, Yongqian Shu, Caicun Zhou, Xiaorong Dong, Yunpeng Liu, Yunchao Huang, Jian Zhao, Yiping Zhang, Sheng Hu, Xiaoyan Lin, Yueyin Pan, Jiuwei Cui, Lizhu Lin, Kangsheng Gu, Yun Fan, Qun Chen, Gongyan Chen, Zhehai Wang, Fengying Wu, Guangyu An, Shuliang Guo, Xiaodong Jiang, Yongsheng Wang, Jifeng Feng, Jianhua Shi, QiMing Wang, Jianan Huang, Lejie Cao, Jianhua Chang, Zhiyong He, Jian Fang, Faguang Jin, Hongjun Gao, Cuimin Ding, Xiangdong Zhou, Anwen Liu, Jianjin Huang, Beili Gao, Yinglan Chen, Chengping Hu, Zhigao Wang, Xinjing Ma

Get full text